Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-22T18:56:15.303Z Has data issue: false hasContentIssue false
  • English
  • Français

Factors Associated with the Prodromal Progression of Schizophrenia that Influence the Course of the Illness

Published online by Cambridge University Press:  07 November 2014

Robert G. Bota ,
Kemal Sagduyu  and
J. Stuart Munro
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

This study examined factors influencing the prognosis of patients with different prodromal manifestations of schizophrenia and the association of diagnosis and antipsychotic treatment with the frequency of future acute inpatient care.

Methods:

Data was collected from the medical records of 24 patients initially diagnosed with schizophrenia.

Results:

Seventy-six percent of the patients (N=18) had at least one psychiatric assessment before the debut of schizophrenia. Patients who were assessed prior to the initial diagnosis of schizophrenia presented in two distinct time frames. Patients in the first wave received a different Axis I diagnosis, depending on the phase of prodrome upon time of initial evaluation. Receiving any Axis I diagnosis during the prodromal stage in wave one correlated with an increased need for acute inpatient treatment (P<.0001) in the following 3 years. Among the patients in wave two, those who received antipsychotic treatment required less acute inpatient care than those who did not (P=.004).

Conclusion:

Obtaining a psychiatric history of assessments and interventions during the prodromal period of schizophrenia can be useful for prognosis.

Type
Original Research
Information
CNS Spectrums , Volume 10 , Issue 12 , December 2005 , pp. 937 - 942
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Lincoln, C, Harrigan, S, McGorry, PD. Understanding the topography of the early psychosis pathways. An opportunity to reduce delays in treatment. Br J Psychiatry Suppl. 1998;172:21–25.Google Scholar
2.Yung, AR, McGorry, PD, McFarlane, CA, et al.Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 1996;22:283–303.Google Scholar
3.Ebel, H, Gross, G, Klosterkotter, J, Huher, G. Basic symptoms in schizophrenic and affective psychoses. Psychvpathology. 1989;22:224–232.Google Scholar
4.McGorry, PD, Edwards, J, Mihalopoulos, C, Jackson, Harrigan SM. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull. 1996;22:305–326.CrossRefGoogle ScholarPubMed
5.Anderson, KN, ed. Mosby's Medical, Nursing, & Allied Health Dictionary. St. Louis, MO: Mosby; 1998.Google Scholar
6.Bleuler, E. Dementia Praecox oder Gruppe der Schizophrenien. Tuebingen, Germany: Archiv der Edition Discord; 1988.Google Scholar
7.Huber, G. Prodromal symptoms in schizophrenia [German]. Fortschr Neurol Psychiatr. 1995;63:131–138.Google Scholar
8.Huber, G, Gross, G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Prog Med. 1989;80:646–652.Google Scholar
9.Yung, AR, McGorry, PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry. 1996;30:587–599.Google Scholar
10.Keith, SJ, Matthews, SM. The diagnosis of schizophrenia: a review of onset and duration issues. Schizophr Bull. 1991;17:51–67.Google Scholar
11.Beiser, M, Erickson, D, Fleming, JA, Iacono, WG. Establishing the onset of psychotic illness. Am J Psychiatry. 1993;150:1349–1354.Google Scholar
12.Loebel, AD, Lieberman, JA, Alvir, JM, et al.Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992;149:1183–1188.Google Scholar
13.Moller, P, Husby, R. The initial prodrome in schizophrenia: searching for naturalistic core dimensions of experience and behavior. Schizophr Bull. 2000;26:217–32.Google Scholar
14.Diagnostic and Statistic Manual of Mental Disorders. 3rd ed. rev. Washington, DC: American Psychiatric Association; 1987.Google Scholar
15.Klosterkotter, J, Hellmich, M, Steinmeyer, EM, Schultze-Lutter, F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58:158–64.Google Scholar
16.Hambrecht, M, Lammertink, M, Klosterkotter, J, et al.Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic. Br J Psychiatry SuppL 2002;43:s30–s37.CrossRefGoogle Scholar
17.Miller, TJ, McGlashan, TH, Rosen, JL, et al.Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159:863–865.Google Scholar
18.Yung, AR, Phillips, LJ, Yuen, HP, et al.Psychosis prediction; 12-month follow up of a high-risk (“prodromal”) group. Schizophr Res. 2003;60:21–32.Google Scholar
19.Cornblatt, BA, Lencz, T, Kane, JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res. 2001;51:31–38.Google Scholar
20.Henn, FA, Lader, M. Medication-free research with schizophrenic patients. A European perspective. Arch Gen Psychiatry. 1997;54:412–413.Google Scholar
21.Marshall, KG. Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits. CMAJ. 1996;154:1837–1843.Google ScholarPubMed
22.McGorry, PD, Yung, A, Phillips, L. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res. 2001;51:17–29.Google Scholar
23.Peterson, DR. The ethics of research into schizophrenia prevention: a carer's perspective. Aust N Z J Psychiatry. 2000;34 Suppl:S201–S203.Google Scholar
24.Tsuang, MT, Stone, WS, Faraone, SV. Understanding predisposition to schizophrenia: toward intervention and prevention. Can J Psychiatry. 2002;47:518–526.Google Scholar
25.Miller, TJ, Zipursky, RB, Perkins, D, et al.The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the “prodromal” sample. Schizophr Res. 2003;61:19–30.Google Scholar
26.Woods, SW, Breier, A, Zipursky, RB, et al.Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry. 2003;54:453–464.Google Scholar
27.McGorry, PD, Yung, AR, Phillips, LJ, et al.Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59:921–928.Google Scholar
28.Falloon, IR, Coverdale, JH, Laidlaw, TM, et al.Early intervention for schizophrenic disorders. Implementing optimal treatment strategies in routine clinical services. OTP Collaborative Group. Br J Psychiatry Suppl. 1998;172:33–38.Google Scholar
29.Cornblatt, BL, Correll, C, Auther, A, Smith, C. Treating the prodrome:naturalistic findings from the RAP program. Acta Psychiatr Scand. 2002;106:44.Google Scholar
30.Cannon, TD, Huttunen, MO, Dahlstrom, M, et al.Antipsychotic drug treatment in the prodromal phase of schizophrenia. Am J Psychiatry. 2002;159:1230–1232.Google Scholar
31.Remington, G, Shammi, C. The use of pharmacotherapy in the prodrome of schizophrenia. CNS Spectr. 2004;9:579–586.Google Scholar
32.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. text rev. Washington, DC: American Psychiatric Association; 2000.Google Scholar
33.Flemenbaum, A, Zimmermann, RL. Inter- and intra-rater reliability of the Brief Psychiatric Rating Scale. Psychol Rep. 1973;32:783–792.Google Scholar
34.Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.CrossRefGoogle ScholarPubMed
35.SPSS, version 8. Windows ed. Chicago, Ill: SPSS, Inc.Google Scholar
36.Tribble, DA. The Health Insurance Portability and Accountability Act: security and privacy requirements. Am J Health Syst Pharm. 2001;58:763–770.CrossRefGoogle ScholarPubMed
37.Lincoln, CV, McGorry, P. Who cares? Pathways to psychiatric care for young people experiencing a first episode of psychosis. Psychiatr Serv. 1995;46:1166–1171.Google Scholar
38.Elkhazen, C, Chauchot, F, Canceil, O, Krebs, MO, Bayle, FJ. Prodromal symptoms of schizophrenia [French]. Encephale. 2003;29:469–477.Google Scholar
39.Giorgi, A. The phenomenological movement and research in the human sciences. Nurs Sci Q. 2005;18:75–82.Google Scholar
40.Gruhle, HW. Schizophrenia [German]. Medizinische. 1952;20:1585–1588.Google Scholar
41.Mayer-Gross, W. Model psychoses, their history, relevancy and limitations. Am J Psychiatry. 1959;115:673–682.CrossRefGoogle ScholarPubMed
42.Klosterkotter, J, Ebel, H, Schultze-Lutter, F, Steinmeyer, EM. Diagnostic validity of basic symptoms. Eur Arch Psychiatry Clin Neurosci. 1996;246:147–154.Google Scholar
43.Yung, AR, Phillips, LJ, McGorry, PD, et al.Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl. 1998;172:14–20.Google Scholar
44.Hafner, H, Maurer, K, Ruhrmann, S, et al.Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci. 2004;254:117–128.Google Scholar
45.Shepherd, M, Watt, D, Falloon, I, Smeeton, N. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl. 1989;15:1–46.Google Scholar